Market Research Report
Asia Pacific Biochips Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||603655|
|Published||Content info||88 Pages
Delivery time: 2-3 business days
|Asia Pacific Biochips Market Forecast 2019-2027|
|Published: March 9, 2019||Content info: 88 Pages||
The revenue generated by the Asia-Pacific biochip market is expected to increase from $XX million in 2018 and reach up to $XX million by 2027, progressing with an estimated CAGR of 21.30% between the forecast years of 2019-2027.
The microarray market is influential for the advancement of the biochip market. Therefore, the development of microarray technologies and improvements in research infrastructure facilities are key growth drivers of the microarray market in the Asia Pacific, which is further proliferating the regional market for biochip technologies.
Technological advancement in biotechnology, the rising number of applications for biochips and the overall scope for biotechnological growth in the sub-continent of Asia are factors that are presenting the market with immense opportunities to expand.
China biochip market accounted for the highest revenue share in 2018, and the nation is expected to showcase a similar growth pattern throughout the forecast period. Other significant markets in this region are Japan, India, South Korea, Australia and those collectively forming the Rest of Asia-Pacific.
However, the complexities of biological systems, high costs of instruments and a lack of common regulatory standards are factors that might challenge this market's growth in the future.
Some of the established players in this market are Bio-Rad Laboratories Inc., Cybrdi Inc., OriGene Technologies Inc., Gamida for Life Group, bioMerieux SA, PerkinElmer Inc., Fluidigm Corporation, IMGENEX, Samsung Electronics Inc., Cepheid Inc., Merck GmbH, Agilent Technology Inc., Thermo Fisher Scientific Inc., Biochain Institute Inc. and Illumina Inc.